摘要:

We have evaluated the expression of Kit, a receptor encoded by the c-kitprotooncogene, and platelet-derived growth factor-receptors (PDGF-R) &agr; and &bgr; in cholangiocarcinoma specimens from 13 separate patients, and provide a case report of a therapeutic trial of imatinib mesylate in one patient. Archived pathologic samples from 13 patients with cholangiocarcinoma were obtained. Tissue sections were hybridized with anti-Kit, anti-PDGF-R&agr; and anti-PDGF-R&bgr; monoclonal antibodies. Kit, PDGF-R&agr; and PDGF-R&bgr; expression was seen in 31, 69 and 46% of samples, respectively. All patients with PDGF-R&bgr; expression also expressed PDGF-R&agr;. Three out of four patients with Kit expression did not express either PDGF receptor and only one patient exhibiting expression of PDGF expressed Kit. Cohen's κ statistic demonstrated that PDGF and Kit expression were inversely correlated with borderline significance (p=0.052; κ=−0.4742, 95% confidence interval –0.9821 to 0.03364). In one case, strong Kit expression was noted in a tumor from a metastatic lymph node, but was absent in the primary tumor, suggesting that Kit may be related to invasive or metastatic potential. Given the high level of expression defined in this study, a prospective clinical trial incorporating imatinib mesylate, alone or in combination with cytotoxic chemotherapy, and especially in chemotherapy-naive patients, should be considered for patients with cholangiocarcinoma.

ISSN:0959-4973    

出版商:OVID    

年代:2003

数据来源: OVID

摘要:

A patient with stage IV malignant melanoma treated with daily radiotherapy and low-dose (100 mg/m2) daily gemcitabine developed a blistering skin eruption, fever and neutropenia consistent with overlap Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). The diagnosis was confirmed by skin biopsy of an affected area. The case history is described, and the literature relating to the development of SJS/TEN in association with chemotherapy and radiotherapy administration is reviewed. This report describes a serious potential complication of concurrent gemcitabine and radiotherapy.

ISSN:0959-4973    

出版商:OVID    

年代:2003

数据来源: OVID

ISSN:0959-4973    

出版商:OVID    

年代:2003

数据来源: OVID

摘要:

Gefitinib is a low-molecular-weight epidermal growth factor receptor tyrosine kinase inhibitor. To date, gefitinib has been administered to over 65 000 people worldwide. The most commonly reported adverse events were diarrhea, acne-like skin rash, nausea, vomiting and asthenia. Most of them were transient and mild in severity. Interstitial lung disease in patients who have been treated with gefitinib is uncommon and has recently been described with an estimated incidence rate of around 1%. We present here a case of fatal drug-induced pulmonary toxicity after therapy with gefitinib for metastatic non-small cell lung cancer. The patient had been treated with gemcitabine and cisplatin, and developed drug-induced hemolytic–uremic syndrome 6 months before gefitinib use.

ISSN:0959-4973    

出版商:OVID    

年代:2003

数据来源: OVID

ISSN:0959-4973    

出版商:OVID    

年代:2003

数据来源: OVID